Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma

Trial Profile

Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Apr 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
    • 19 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 14 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top